|Referral date||01 June 2008|
The above topic was referred to NICE as part of the 17th wave referrals and you were invited to participate in this single technology appraisal in July 2008. Following a detailed review of the number of patients anticipated to be treated by dasatinib for acute lymphoblastic leukaemia, we have concluded that further discussions with the Department of Health are required to establish how best to progress this appraisal.
We are therefore suspending this single technology appraisal whilst we consider the next steps.
|Closing date for invited submissions / evidence submission:||TBC|
|1st appraisal committee meeting:||TBC|
|23 December 2008||Please note that this topic has been removed from the technology appraisals work programme.|
For further information on our processes and methods, please see our CHTE processes and methods manual